BellBrook Labs’ Transcreener® ADP Assay is on Target for…

The ubiquitin-selective chaperone, p97, is emerging as an exciting new therapeutic target for diverse diseases and pathologies, however its low intrinsic ATPase activity has made it difficult to adapt…

(PRWeb April 20, 2012)

Read the full story at http://www.prweb.com/releases/2012/4/prweb9400753.htm


Comments are closed.

Get email updates

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Subscribe!